Top

Published in:

01-02-2021 | Prostate Cancer

The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families

Authors: Beth N. Peshkin, Mary Kate Ladd, Claudine Isaacs, Hannah Segal, Aryana Jacobs, Kathryn L. Taylor, Kristi D. Graves, Suzanne C. O’Neill, Marc D. Schwartz

Published in: Journal of Cancer Education | Issue 1/2021

Abstract

Cascade testing for hereditary breast/ovarian cancer is an important public health priority. Increasing attention has been paid to the relevance of testing for men within BRCA1/2-positive families given that such testing may provide important information about their cancer risks, particularly for prostate cancer, and risks to their offspring. However, men are much less likely to seek genetic counseling and testing than their at-risk female relatives. To facilitate access to pre-test information and testing, we developed a web-based intervention (WI) for men that we are evaluating in a pilot randomized controlled trial (RCT). This paper describes three phases of research in the development of the WI: (1) formative (qualitative) research among men from BRCA1/2 families to assess needs and preferences for education; (2) a detailed description of the organization, format, and content of the WI; and (3) usability testing. We discuss the aims and hypotheses of the pilot RCT in which the WI is being compared with an enhanced usual care condition among at-risk men. We expect that the WI described here will foster informed decisions and lead to increased use of BRCA1/2 counseling and testing, potentially yielding improved cancer control outcomes for this understudied group, and for their at-risk relatives.

Available only for authorised users

Rosenthal ET, Bernhisel R, Brown K, Kidd J, Manley S (2017) Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories. Cancer Genet 218-219:58–68. https://doi.org/10.1016/j.cancergen.2017.09.003CrossRefPubMed

Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35(34):3800–3806. https://doi.org/10.1200/JCO.2017.73.6314CrossRefPubMedPubMedCentral

Febbraro T, Robison K, Wilbur JS, Laprise J, Bregar A, Lopes V, Legare R, Stuckey A (2015) Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol 138(1):109–114. https://doi.org/10.1016/j.ygyno.2015.04.029CrossRefPubMedPubMedCentral

ASCO Connection (2018) Prostate cancer: molecular oncology tumor boards. https://connection.asco.org/discussion/prostate-cancer-august-2018-molecular-oncology-tumor-boards. Accessed 8 Aug 2018

Healio.com (2018) Family history, disease stage key in determining need for inherited prostate cancer genetic testing. https://www.healio.com/hematology-oncology/prostate-cancer/news/in-the-journals/%7b5f648cfd-bfd8-4c50-b684-b5b62a2c7d71%7d/family-history-disease-stage-key-in-determining-need-for-inherited-prostate-cancer-genetic-testing. Accessed 29 Jan

Marcus AD (2018) The genetic test some men don’t know they need. Wall Street J, August 7. https://www.wsj.com/articles/the-genetic-test-some-men-dont-know-they-need-1533651551

Friedman S (2018) Solving for Y: reaching men about genetic testing for hereditary breast, ovarian, pancreatic, prostate and related cancers (HBOC). FORCE blog June 17, 2018. https://www.facingourrisk.org/get-involved/HBOC-community/BRCA-HBOC-blogs/FORCE/uncategorized/solving-for-y-genetic-testing-in-men/

Pritchard CC (2019) New name for breast-cancer syndrome could help to save lives. Nature 571(7763):27–29. https://doi.org/10.1038/d41586-019-02015-7CrossRefPubMed

Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742. https://doi.org/10.1200/JCO.2004.05.055CrossRefPubMed

10.

Kowalewski A, Szylberg L, Saganek M, Napiontek W, Antosik P, Grzanka D (2018) Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol 144(8):1503–1507. https://doi.org/10.1007/s00432-018-2666-9CrossRefPubMedPubMedCentral

11.

Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M, EMBRACE, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S, GEMO Study Collaborators, van Heetvelde M, Poppe B, de Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ, HEBON, Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H, KConFab Investigators, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L (2017) Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol 35(20):2240–2250. https://doi.org/10.1200/JCO.2016.69.4935CrossRefPubMedPubMedCentral

12.

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31(14):1748–1757. https://doi.org/10.1200/JCO.2012.43.1882CrossRefPubMedPubMedCentral

13.

Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S (2016) Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers. Prostate 76(13):1135–1145. https://doi.org/10.1002/pros.23204CrossRefPubMedPubMedCentral

14.

National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology (NCCN guidelines). Genetic/familial high-risk assessment: breast and ovarian. Version 3.2019. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 18 Jan 2019

15.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A’Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697–1708. https://doi.org/10.1056/NEJMoa1506859CrossRefPubMedPubMedCentral

16.

Schepisi G, Farolfi A, Conteduca V, Martignano F, de Lisi D, Ravaglia G, Rossi L, Menna C, Bellia S, Barone D, Gunelli R, de Giorgi U (2017) Immunotherapy for prostate cancer: where we are headed. Int J Mol Sci 18(12). https://doi.org/10.3390/ijms18122627

17.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG (2018) Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus 2017. J Clin Oncol 36(4):414–424. https://doi.org/10.1200/JCO.2017.74.1173CrossRefPubMed

18.

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden A, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, IMPACT Collaborators, Moss S, Eeles RA (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66(3):489–499. https://doi.org/10.1016/j.eururo.2014.01.003CrossRefPubMedPubMedCentral

19.

Grossman DC, Curry SJ, Owens DK et al (2018) Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 319(18):1901–1913. https://doi.org/10.1001/jama.2018.3710CrossRefPubMed

20.

Schwiter R, Rahm AK, Williams JL, Sturm AC (2018) How can we reach at-risk relatives? Efforts to enhance communication and cascade testing uptake: a mini-reivew. Curr Genet Med Rep 6(2):21–27. https://doi.org/10.1007/s40142-018-0134-0CrossRef

21.

Hallowell N, Arden-Jones A, Eeles R, Foster C, Lucassen A, Moynihan C, Watson M (2006) Guilt, blame and responsibility: men’s understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociol Health Illn 28(7):969–988. https://doi.org/10.1111/j.1467-9566.2006.00515.xCrossRefPubMed

22.

Liede A, Metcalfe K, Hanna D, Hoodfar E, Snyder C, Durham C, Lynch HT, Narod SA (2000) Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 67(6):1494–1504. https://doi.org/10.1086/316907CrossRefPubMedPubMedCentral

23.

Rauscher EA, Dean M, Campbell-Salome GM (2018) “I am uncertain about what my uncertainty even is”: Men’s uncertainty and information management of their BRCA-related cancer risks. J Genet Couns 27(6):1417–1427. https://doi.org/10.1007/s10897-018-0276-yCrossRefPubMed

24.

Stromsvik N, Raheim M, Oyen N, Gjengedal E (2009) Men in the women’s world of hereditary breast and ovarian cancer--a systematic review. Familial Cancer 8(3):221–229. https://doi.org/10.1007/s10689-009-9232-1CrossRefPubMed

25.

Suttman A, Pilarski R, Agnese DM, Senter L (2018) “Second-class status?” Insight into communication patterns and common concerns among men with hereditary breast and ovarian cancer syndrome. J Genet Couns 27(4):885–893. https://doi.org/10.1007/s10897-018-0214-zCrossRefPubMed

26.

Childers KK, Maggard-Gibbons M, Macinko J, Childers CP (2018) National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer. JAMA Oncol 4(6):876–879. https://doi.org/10.1001/jamaoncol.2018.0340CrossRefPubMedPubMedCentral

27.

Daly MB (2009) The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling. J Genet Couns 18(1):42–48. https://doi.org/10.1007/s10897-008-9183-yCrossRefPubMed

28.

Facing Our Risk of Cancer Empowered (FORCE) (2018) Paying for genetic services. https://www.facingourrisk.org/understanding-brca-and-hboc/information/finding-health-care/paying_for_testing/basics/overview.php

29.

Fehniger J, Lin F, Beattie MS, Joseph G, Kaplan C (2013) Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers. J Genet Couns 22(5):603–612. https://doi.org/10.1007/s10897-013-9592-4CrossRefPubMed

30.

Graves KD, Gatammah R, Peshkin BN, Krieger A, Gell C, Valdimarsdottir HB, Schwartz MD (2011) BRCA1/2 genetic testing uptake and psychosocial outcomes in men. Familial Cancer 10(2):213–223. https://doi.org/10.1007/s10689-011-9425-2CrossRefPubMedPubMedCentral

31.

Rauscher EA, Dean M (2017) “I’ve just never gotten around to doing it”: Men’s approaches to managing BRCA-related cancer risks. Patient Educ Couns 101(2):340–345. https://doi.org/10.1016/j.pec.2017.07.015CrossRefPubMed

32.

Buchanan AH, Rahm AK, Williams JL (2016) Alternate service delivery models in cancer genetic counseling: a mini-review. Front Oncol 6(120). https://doi.org/10.3389/fonc.2016.00120

33.

Gordon ES, Babu D, Laney DA (2018) The future is now: technology’s impact on the practice of genetic counseling. Am J Med Genet C Semin Med Genet 178(1):15–23. https://doi.org/10.1002/ajmg.c.31599CrossRefPubMed

34.

Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Kinney AY, Luta G, Kelleher S, Leventhal KG, Vegella P, Tong A, King L (2014) Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 32(7):618–626. https://doi.org/10.1200/JCO.2013.51.3226CrossRefPubMedPubMedCentral

35.

Biesecker BB, Lewis KL, Biesecker LG (2018) Web-based platform vs genetic counselors in educating patients about carrier results from exome sequencing--reply. JAMA Intern Med 178(7):999–346. https://doi.org/10.1001/jamainternmed.2017.8049CrossRefPubMed

36.

Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW (2019) Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative. J Natl Cancer Inst 111(1):95–98. https://doi.org/10.1093/jnci/djy147CrossRefPubMed

37.

Sturm AC, Schmidlen T, Scheinfeldt L, Hovick S, McElroy J, Toland A, Roberts J, Sweet K (2018) Early outcome data assessing utility of a post-test genomic counseling framework for the scalable delivery of precision health. J Pers Med 8(3). https://doi.org/10.3390/jpm8030025

38.

Juan AS, Wakefield CE, Kasparian NA, Kirk J, Tyler J, Tucker K (2008) Development and pilot testing of a decision aid for men considering genetic testing for breast and/or ovarian cancer-related mutations (BRCA1/2). Genet Test 12(4):523–532. https://doi.org/10.1089/gte.2008.0035CrossRefPubMed

39.

Butrick M, Kelly S, Peshkin BN, Luta G, Nusbaum R, Hooker GW, Graves K, Feeley L, Isaacs C, Valdimarsdottir HB, Jandorf L, DeMarco T, Wood M, McKinnon W, Garber J, McCormick SR, Schwartz MD (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17(6):467–475. https://doi.org/10.1038/gim.2014.125CrossRefPubMed

40.

Interrante MK, Segal H, Peshkin BN, Valdimarsdottir HB, Nusbaum R, Similuk M, DeMarco T, Hooker G, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Heinzmann J, Kinney AY, Schwartz MD (2017) Randomized noninferiority trial of telephone vs in-person genetic counseling for hereditary breast and ovarian cancer: a 12-month follow-up. JNCI Cancer Spectr 1(1):pkx002. https://doi.org/10.1093/jncics/pkx002CrossRefPubMedPubMedCentral

41.

Peshkin BN, Demarco TA, Graves KD et al (2008) Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test 12(1):37–52. https://doi.org/10.1089/gte.2006.0525CrossRefPubMed

42.

Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O’Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K (2018) Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients. Breast Cancer Res Treat 170(3):517–524. https://doi.org/10.1007/s10549-018-4773-3CrossRefPubMedPubMedCentral

43.

Michie S, Dormandy E, Marteau TM (2002) The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns 48(1):87–91. https://doi.org/10.1016/S0738-3991(02)00089-7CrossRefPubMed

44.

Michie S, Dormandy E, Marteau TM (2003) Informed choice: understanding knowledge in the context of screening uptake. Patient Educ Couns 50(3):247–253. https://doi.org/10.1016/S0738-3991(03)00044-2CrossRefPubMed

45.

The Ottawa Hospital Research Institute (2015) Ottawa Decision Support Framework (ODSF). 22 June. https://decisionaid.ohri.ca/odsf.html

46.

Nusbaum R, Leventhal KG, Hooker GW, Peshkin BN, Butrick M, Salehizadeh Y, Tuong W, Eggly S, Mathew J, Goerlitz D, Shields PG, Schwartz MD, Graves KD (2013) Translational genomic research: protocol development and initial outcomes following SNP testing for colon cancer risk. Transl Behav Med 3(1):17–29. https://doi.org/10.1007/s13142-012-0149-0CrossRefPubMed

47.

Kaufman EM, Peshkin BN, Lawrence WF, Shelby R, Isaacs C, Brown K, Rispoli J, O’Neill S, Hurley K, DeMarco T, Brogan B, Grumet S, Jandorf L, McKenna K, Valdimarsdottir H, Schwartz MD (2003) Development of an interactive decision aid for female BRCA1/BRCA2 carriers. J Genet Couns 12(2):109–129. https://doi.org/10.1023/A:1022698112236CrossRefPubMed

48.

Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD (2018) Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med. https://doi.org/10.1093/tbm/iby101

49.

Dorfman CS, Williams RM, Kassan EC, Red SN, Dawson DL, Tuong W, Parker ER, Ohene-Frempong J, Davis KM, Krist AH, Woolf SH, Schwartz MD, Fishman MB, Cole C, Taylor KL (2010) The development of a web- and a print-based decision aid for prostate cancer screening. BMC Med Inform Decis Mak 10(12). https://doi.org/10.1186/1472-6947-10-12

50.

Taylor KL, Davis JL, 3rd, Turner RO, et al. (2006) Educating African American men about the prostate cancer screening dilemma: a randomized intervention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 15(11): 2179–2188. https://doi.org/10.1158/1055-9965.epi-05-0417

51.

Taylor KL, Williams RM, Davis K, Luta G, Penek S, Barry S, Kelly S, Tomko C, Schwartz M, Krist AH, Woolf SH, Fishman MB, Cole C, Miller E (2013) Decision making in prostate cancer screening using decision aids vs usual care: a randomized clinical trial. JAMA Intern Med 173(18):1704–1712. https://doi.org/10.1001/jamainternmed.2013.9253CrossRefPubMedPubMedCentral

52.

Williams RM, Davis KM, Luta G, Edmond SN, Dorfman CS, Schwartz MD, Lynch J, Ahaghotu C, Taylor KL (2013) Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer. Patient Educ Couns 91(3):329–336. https://doi.org/10.1016/j.pec.2012.12.013CrossRefPubMedPubMedCentral

53.

Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161. https://doi.org/10.1007/s10897-011-9462-xCrossRefPubMed

54.

ClinicalTrials.gov (2019) The IMPACT study - identification of men with a genetic predisposition to prostate cancer: targeted screening in BRCA1/2 mutation carriers & controls. https://clinicaltrials.gov/ct2/show/NCT00261456

55.

United Breast Cancer Foundation (2016) Male self breast exam. http://ubcf.org/male-self-breast-exam/

56.

Thomas MH, Higgs LK, Modesitt SC, Schroen AT, Ring KL, Dillon PM (2019) Cases and evidence for panel testing in cancer genetics: is site-specific testing dead? J Genet Couns 28:1–8. https://doi.org/10.1002/jgc4.1044CrossRef

57.

Facing Our Risk of Cancer Empowered (FORCE) (2018) If cancer runs in your family...information about BRCA testing for men. https://www.facingourrisk.org/understanding-brca-and-hboc/publications/documents/Info%20for%20Men%20Flyer%207.16.14.pdf

58.

Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH (2005) Development and validation of a breast cancer genetic counseling knowledge questionnaire. Patient Educ Couns 56(2):182–191. https://doi.org/10.1016/j.pec.2004.02.007CrossRefPubMed

59.

Dormandy E, Hankins M, Marteau E (2006) Attitudes and uptake of a screening test: the moderating role of ambivalence. Psychol Health 21(4):499–511. https://doi.org/10.1080/14768320500380956CrossRef

60.

O'Connor AM (1995) Validation of a decisional conflict scale. Med Decis Mak 15(1):25–30. https://doi.org/10.1177/0272989X9501500105CrossRef

61.

Bancroft EK, Castro E, Ardern-Jones A, Moynihan C, Page E, Taylor N, Eeles RA, Rowley E, Cox K (2014) “It’s all very well reading the letters in the genome, but it’s a long way to being able to write”: Men’s interpretations of undergoing genetic profiling to determine future risk of prostate cancer. Familial Cancer 13(4):625–635. https://doi.org/10.1007/s10689-014-9734-3CrossRefPubMed

62.

Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, Padonu G, Talarczyk G (1996) Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Mak 16(1):58–64. https://doi.org/10.1177/0272989X9601600114CrossRef

63.

Schwartz MD, Valdimarsdottir HB, Demarco TA et al (2009) Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol 28(1):11–19. https://doi.org/10.1037/a0013147CrossRefPubMedPubMedCentral

64.

Horowitz M, Wilner N, Alvarez W (1979) Impact of event scale: a measure of subjective stress. Psychosom Med 41(3):209–218 http://www.ncbi.nlm.nih.gov/pubmed/472086CrossRef

65.

Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C (2002) A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol 21(6):564–572. https://doi.org/10.1037/0278-6133.21.6.564CrossRefPubMed

66.

Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24(4):385–396 http://www.jstor.org/stable/2136404CrossRef

67.

Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A (1991) Psychological side effects of breast cancer screening. Health Psychol 10(4):259–267 http://www.ncbi.nlm.nih.gov/pubmed/1915212CrossRef

68.

Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D (2011) Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS^(R)): depression, anxiety, and anger. Assessment 18(3):263–283. https://doi.org/10.1177/1073191111411667CrossRefPubMedPubMedCentral

69.

Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D (2009) Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res 18(7):873–880. https://doi.org/10.1007/s11136-009-9496-9CrossRefPubMedPubMedCentral

70.

George R, Kovak K, Cox SL (2015) Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases. J Genet Couns 24(3):388–399. https://doi.org/10.1007/s10897-014-9805-5CrossRefPubMed

71.

Tuffaha HW, Mitchell A, Ward RL, Connelly L, Butler JRG, Norris S, Scuffham PA (2018) Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genet Med 20(9):985–994. https://doi.org/10.1038/gim.2017.231CrossRefPubMed

72.

Dotson WD, Douglas MP, Kolor K, Stewart AC, Bowen MS, Gwinn M, Wulf A, Anders HM, Chang CQ, Clyne M, Lam TK, Schully SD, Marrone M, Feero WG, Khoury MJ (2014) Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther 95(4):394–402. https://doi.org/10.1038/clpt.2013.226CrossRefPubMedPubMedCentral

Title: The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families
Authors: Beth N. Peshkin
Mary Kate Ladd
Claudine Isaacs
Hannah Segal
Aryana Jacobs
Kathryn L. Taylor
Kristi D. Graves
Suzanne C. O’Neill
Marc D. Schwartz
Publication date: 01-02-2021
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Published in: Journal of Cancer Education / Issue 1/2021
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI: https://doi.org/10.1007/s13187-019-01599-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Cancer Awareness and Understanding of Students in Japan: What Do Students Having Close Relatives with Cancer Think About the Disease?

Quantitative Assessment of Learning Behaviors for Oncology Providers

Non-oncologist Physician Knowledge of Radiation Therapy at an Urban Community Hospital

Integrating Concept Maps into a Medical Student Oncology Curriculum

Twenty-first Century Bedside Manner: Exploring Patient-Centered Communication in Secure Messaging with Cancer Patients

Development and Usability Testing of a Decision Support App for Women Considering Breast Reconstruction Surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer